Neogen Corporation
NASDAQ:NEOGMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $2.42B
- Beta
- 1.80
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$2.80
Volume 1.79M
Average 2.53M
NEOG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Neogen CorporationNASDAQ: NEOG
Research & Development · Q1 FY2027 · quarter ended Aug 2026
Research & development growth accelerates
Q1 FY2027 research & development of $6.5M rose 26.8% year over year, ahead of the -5.9% change in trailing-twelve-month research & development. Sequentially, it rose 32.7% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Research & development amounted to 2.1% of revenue in FY2026, down 0.2 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +26.8% holds above the trailing-twelve-month pace of -5.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 18.4M USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- +1.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-05-31 | 18.4M | -12.7% |
| FY2025 | 2025-05-31 | 21.09M | -6.2% |
| FY2024 | 2024-05-31 | 22.48M | -13.7% |
| FY2023 | 2023-05-31 | 26.04M | +52.7% |
| FY2022 | 2022-05-31 | 17.05M | — |
Research & Development vs competitors
How NEOG compares with its peers on the latest reported figures
- NEOG's LTM Aug 2026 research & development of $19.76M is the 6th highest of the 7 companies compared; the peer median is $323.93M.
- Its year-over-year change of -5.9% is the 5th highest of 6, against a peer median of +7.0%.
- Research & development amounts to 2.2% of revenue for NEOG, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B | +65.7% | -2.6% | 42.7% | |
| LTM Jun 2026 | $722M | +5.9% | +9.0% | 7.6% | |
| LTM Sep 2026 | $381M | +7.0% | +4.7% | 7.4% | |
| LTM Sep 2026 | $266.87M | +10.2% | -0.5% | 5.7% | |
| LTM Sep 2026 | $20.81M | -10.1% | +14.9% | 1.9% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NEOG) | $323.93M | +7.0% | +4.7% | 6.6% | |
Competitors are the stored peer set for NEOG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 | FY2026 May 2026 |
|---|---|---|---|---|---|
| Revenue | 527.16M | 822.45M | 924.22M | 894.66M | 870.4M |
| Cost of Revenue | 284.15M | 416.49M | 461.59M | 473.29M | 461.9M |
| Gross Profit | 243.01M | 405.96M | 462.64M | 421.38M | 408.5M |
| Gross Margin | 46.1% | 49.4% | 50.1% | 47.1% | 46.9% |
| Research & Development | 17.05M | 26.04M | 22.48M | 21.09M | 18.4M |
| Selling, General & Admin | 167.35M | 342.4M | 382.76M | 401.97M | 411.7M |
| Operating Expenses | 184.4M | 368.44M | 385.21M | 411.96M | 430.1M |
| Depreciation & Amortization | 24.13M | 90.47M | 121.23M | 125.67M | 116.3M |
| EBITDA | 84.34M | 124.39M | 182.6M | (937.75M) | 164.9M |
| EBITDA Margin | 16.0% | 15.1% | 19.8% | -104.8% | 18.9% |
| Operating Income | 58.62M | 37.52M | 77.43M | 9.42M | (21.6M) |
| Operating Margin | 11.1% | 4.6% | 8.4% | 1.1% | -2.5% |
| Interest Income | 1.34M | 3.17M | 6.36M | 3.11M | 0 |
| Interest Expense | 72K | 55.96M | 73.39M | 71.62M | 57.6M |
| Other Income / Expenses | 1.59M | (59.56M) | (91.73M) | (1.14B) | 12.6M |
| Income Before Tax | 60.21M | (22.04M) | (14.31M) | (1.13B) | (9M) |
| Pre-Tax Margin | 11.4% | -2.7% | -1.5% | -126.7% | -1.0% |
| Income Tax Expense | 11.9M | 828K | (4.88M) | (41.07M) | (1.1M) |
| Net Income | 48.31M | (22.87M) | (9.42M) | (1.09B) | (7.9M) |
| Net Margin | 9.2% | -2.8% | -1.0% | -122.1% | -0.9% |
| EPS (Basic) | 0.45 | (0.12) | (0.04) | (5.03) | (0.04) |
| EPS (Diluted) | 0.45 | (0.12) | (0.04) | (5.03) | (0.04) |
| Weighted Avg Shares | 107.68M | 188.88M | 216.48M | 216.89M | 217.5M |
| Weighted Avg Shares (Diluted) | 108.02M | 188.88M | 216.48M | 216.89M | 217.5M |
Neogen Corporation
NASDAQ:NEOG
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.